Cempra, Inc. (CEMP)
(Delayed Data from NSDQ)
$2.33 USD
+0.03 (1.09%)
Updated Nov 3, 2017 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Melinta Therapeutics, Inc. [CEMP]
Reports for Purchase
Showing records 1 - 20 ( 89 total )
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for CEMP
Provider: ValuEngine, Inc
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
To Merge With Melinta, Creating Antibiotic-Focused Biopharma Firm
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Taksta?s Phase 2/3 Fully Enrolled; Data in 30 rBJI Patients in 2H''17
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Soli''s Effectively Dq?d; Taksta?s Bone Inf Ph2/3 Almost Fully Enrolled
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Taksta Hits on First ABSSSI Ph3; Bone Inf Data Ahead; Upgrade to Buy, $8 PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
FDA Issues CRL, Requires Large Safety Study For Solithromycin?s Approval
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M